Trials / Unknown
UnknownNCT02813486
Safety and Immunogenicity Study of Tetanus, Diphtheria and Acellular Pertussis (Tdap) Vaccine
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 220 (estimated)
- Sponsor
- Green Cross Corporation · Industry
- Sex
- All
- Age
- 19 Years – 64 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate safety of GC3111 and to describe immunogenicity of a single dose of GC3111 versus Boostrix® vaccine among healthy adults in 19 to \<65 years of age.
Detailed description
To evaluate immunogenicity of GC3111 as tetanus, diphtheria and acellular pertussis (Tdap) vaccine in healthy adults. To evaluate safety (solicited adverse events) of GC3111 in healthy adults.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Biological: GC3111 vaccine | 0.5mL, Intramuscular |
| BIOLOGICAL | Biological: Boostrix® vaccine | 0.5mL, Intramuscular |
Timeline
- Start date
- 2016-06-01
- Primary completion
- 2016-11-01
- Completion
- 2016-11-01
- First posted
- 2016-06-27
- Last updated
- 2016-11-07
Locations
5 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02813486. Inclusion in this directory is not an endorsement.